Advanced Materials

Cancer Therapy: Diamond-Lipid Hybrids Enhance Chemotherapeutic Tolerance and Mediate Tumor Regression (Adv. Mater. 26/2013)

Authors

  • Laura Moore,

    1. Department of Biomedical Engineering, Northwestern University, Evanston, Illinois, 60208, USA
    Current affiliation:
    1. L. K. M. and E. K. C. contributed equally to this work.
    Search for more papers by this author
  • Edward Kai-Hua Chow,

    1. George Williams Hooper Foundation, University of California San Francisco, San Francisco, California, 94143, USA
    2. Cancer Science Institute of Singapore, Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117599
    Current affiliation:
    1. L. K. M. and E. K. C. contributed equally to this work.
    Search for more papers by this author
  • Eiji Osawa,

    1. NanoCarbon Research Institute, Shinshu University, Ueda, Nagano, Japan
    Search for more papers by this author
  • J. Michael Bishop,

    1. Department of Microbiology and Immunology, George Williams Hooper Foundation, University of California San Francisco, San Francisco, California, 94143, USA
    Search for more papers by this author
  • Dean Ho

    Corresponding author
    1. Department of Biomedical Engineering, Northwestern University, Evanston, Illinois, 60208, USA
    2. Department of Mechanical Engineering, Northwestern University, Evanston, Illinois, 60208, USA
    3. Institute for Bionanotechnology in Medicine (IBNAM), Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago. Illinois, 60611, USA
    4. Division of Oral Biology and Medicine, Division of Advanced Prosthodontics, The Jane and Jerry Weintraub Center for Reconstructive Biotechnology, UCLA School of Dentistry, UCLA Department of Bioengineering, Jonsson Comprehensive Cancer Center, California NanoSystems Institute, Los Angeles, California, 90095, USA
    • Department of Biomedical Engineering, Northwestern University, Evanston, Illinois, 60208, USA.
    Search for more papers by this author

Abstract

To facilitate targeted drug delivery using nanodiamond (ND) vehicles, epirubicin-functionalized ND/lipid hybrids are coupled to epidermal growth factor receptor (EGFR) antibodies. The resulting particles mediate tumor regression, and markedly improve drug tolerance in a triplenegative breast cancer model in vivo. Furthermore, comprehensive biocompatibility analysis following intravenous ND administration indicate that the particles are well tolerated by mice. Further information can be found in the article by Dean Ho and co-workers on page 3532.

original image

Ancillary